The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1362
April 18, 2011
View Complete Issue         Table of Contents 2019 
A New Testosterone Gel (Fortesta) for Hypogonadism
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A New Testosterone Gel (Fortesta) for Hypogonadism
April 18, 2011 (Issue: 1362)
The FDA has approved Fortesta (Endo), a topical gel, for testosterone replacement therapy in adult males with hypogonadism. It is classified as a Schedule III controlled substance. Table 1 lists some available testosterone products, including 2...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Testosterone Gel (Fortesta) for Hypogonadism
Article code: 1362b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.